Aligos Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
ALGS$2.57-34.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
(Unaudited, in thousands, except share and per share data)
| Common Stock · AdditionalPaid-in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Income | Equity (Deficit) | |
| Balance as of December 31, 2024 | 3,864,436 | $8 | $588,576 | $(618,008) | $451 | $(28,973) |
| Issuance of common stock related to RSU vesting | 590 | - | - | - | - | - |
| Issuance of common stock upon net exercise of pre-funded warrants | 146,468 | - | - | - | - | - |
| Issuance of common stock, pre-funded warrants and common warrants in connection with 2025 PIPE offering | 2,103,307 | 1 | 105,003 | - | - | 105,004 |
| Costs related to 2025 PIPE offering | - | - | (3,629) | - | - | (3,629) |
| Stock-based compensation expense related to employee stock awards | - | - | 909 | - | - | 909 |
| Stock-based compensation expense related to employee stock purchases | - | - | 50 | - | - | 50 |
| Other comprehensive loss | - | - | - | - | (4) | (4) |
| Net income | - | - | - | 43,088 | - | 43,088 |
| Balance as of March 31, 2025 | 6,114,801 | $9 | $690,909 | $(574,920) | $447 | $116,445 |
| Common Stock · AdditionalPaid-in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’ | ||||||
| Shares | Amount | Capital | Deficit | Income | Equity | |
| Balance as of December 31, 2023 | 3,003,855 | $7 | $578,325 | $(486,797) | $545 | $92,080 |
| Issuance of common stock upon exercise of pre-funded warrants | 22,771 | - | - | - | - | - |
| Issuance of common stock from RSU vesting | 97 | - | - | - | - | - |
| Stock-based compensation expense related to employee stock awards | - | - | 2,500 | - | - | 2,500 |
| Stock-based compensation expense related to employee stock purchases | - | - | 148 | - | - | 148 |
| Other comprehensive loss | - | - | - | - | (69) | (69) |
| Net loss | - | - | - | (34,863) | - | (34,863) |
| Balance as of March 31, 2024 | 3,026,723 | $7 | $580,973 | $(521,660) | $476 | $59,796 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.